Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director James C. Smith acquired 1,664.201 phantom stock units as deferred compensation, increasing his beneficial ownership to 170,424.763 units.

Summary

• James C. Smith, a Director at Pfizer Inc. (PFE), acquired 1,664.201 phantom stock units.
• The transaction date for this acquisition was March 27, 2026.
• Each phantom stock unit represents one phantom share of common stock and was valued at $27.04.
• These units are part of deferred director's compensation, including dividend equivalents, and will be settled in cash or common stock at the director's election upon retirement from the Board.
• Following this transaction, James C. Smith beneficially owns a total of 170,424.763 phantom stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While a routine compensation filing, it signifies continued director alignment with shareholder interests through equity-linked compensation.

Positives

• The acquisition of phantom stock units by a director aligns their interests with those of shareholders, as the value of their compensation is tied to the company's stock performance.
• This transaction represents a routine component of director compensation, indicating stable corporate governance practices.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that the use of phantom stock units as a form of deferred compensation for non-employee directors is a common practice across large, publicly traded companies in the pharmaceutical and other industries. This mechanism is designed to align the long-term interests of directors with those of shareholders by tying a portion of their compensation to the company's stock performance without immediate equity issuance.

Comparison to Industry Standards

• Deferred compensation plans, often utilizing phantom stock or restricted stock units, are standard practice for non-executive directors in major pharmaceutical companies like Johnson & Johnson, Merck, and Bristol Myers Squibb. These plans typically vest over time or are settled upon retirement, similar to Pfizer's arrangement.
• The structure of these units, which include dividend equivalents, is also a common feature in such compensation schemes, ensuring directors benefit from shareholder returns beyond just stock price appreciation.

Related Party Transactions

• The acquisition of phantom stock units by James C. Smith, a Director of Pfizer, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine director compensation event and does not provide new information that would fundamentally alter the investment thesis for Pfizer. It reinforces director alignment but is not a catalyst for a change in recommendation based solely on this report.

Keywords

Pfizer, PFE, Insider Transaction, Form 4, Phantom Stock Units, Director Compensation, Equity Compensation, James C. Smith